Skip to main content
Premium Trial:

Request an Annual Quote

Novasep, Chromatide Extend Synthetic Peptide, Oligo Partnership

NEW YORK (GenomeWeb News) – Chromatide and Novasep have agreed to extend a research partnership focused on developing peptide and oligonucleotide synthesis technology, Novasep said Friday.
Novasep said the companies plan to combine its synthesis and purification services, which pharmaceutical companies use to produce pure peptides and oligonucleotides, with Chromatide’s experience in peptide and oligonucleotide synthesis, including production of novel resins and instruments.
“Peptide manufacturers lack a cost efficient, automated solid phase synthesis technology,” explained Novasep Process Pharma Business Unit President Jean Blehaut, adding that the combined systems “will allow us to provide a unique, global process solution for peptides” and for oligonucleotide makers.
Novasep plans to launch the synthesis systems the companies have developed later this year, Chromatide CSO Don Wellings said in a statement.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.